NICE "yes" for Allergan's Ozurdex after comparison with off-label Avastin
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has recommended Allergan's dexamethasone intravitreal implant Ozurdex as an option for treating macular oedema following central and branch retinal vein occlusion (CRVO/BRVO). The yes came as NICE "commended" Allergan for its attempt to compare the relative clinical and cost effectiveness of Ozurdex and Roche's anticancer Avastin (bevacizumab).
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.